A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
Clinical trial NCT05028556 · COMPLETED
Trial details
- NCT number
- NCT05028556
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-06
- Primary completion
- 2024-07-05
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.